Treatment of premenstrual dysphoric disorder with selective serotonin reuptake inhibitors
- PMID:14524645
- DOI: 10.1592/phco.23.10.1131.32754
Treatment of premenstrual dysphoric disorder with selective serotonin reuptake inhibitors
Abstract
Premenstrual dysphoric disorder (PMDD) is considered a severe form of premenstrual syndrome. Symptoms of PMDD occur during the last week of the luteal phase of the menstrual cycle and usually abate at the onset of menses. About 3-8% of all menstruating women experience PMDD, which can lead to significant functional impairment. Several randomized, controlled trials have assessed the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of PMDD. The SSRIs were found to significantly improve symptoms, particularly psychological or behavioral symptoms, during the luteal phase in women with PMDD. Also, SSRIs were found to improve the quality of life in women with PMDD. Headache, fatigue, insomnia, and anxiety were often reported as adverse effects. A decrease in libido or sexual dysfunction also was reported. In recent studies, intermittent SSRI therapy was found to be effective treatment for PMDD and allows a woman to take the drug for only 14 days each month. Intermittent SSRI therapy should be recommended before continuous daily dosing of SSRIs in the treatment of PMDD.
Similar articles
- Selective serotonin reuptake inhibitors for premenstrual syndrome.Marjoribanks J, Brown J, O'Brien PM, Wyatt K.Marjoribanks J, et al.Cochrane Database Syst Rev. 2013 Jun 7;2013(6):CD001396. doi: 10.1002/14651858.CD001396.pub3.Cochrane Database Syst Rev. 2013.Update in:Cochrane Database Syst Rev. 2024 Aug 14;8:CD001396. doi: 10.1002/14651858.CD001396.pub4.PMID:23744611Free PMC article.Updated.Review.
- Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?Pearlstein T.Pearlstein T.Drugs. 2002;62(13):1869-85. doi: 10.2165/00003495-200262130-00004.Drugs. 2002.PMID:12215058Review.
- Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K.Steiner M, et al.J Womens Health (Larchmt). 2006 Jan-Feb;15(1):57-69. doi: 10.1089/jwh.2006.15.57.J Womens Health (Larchmt). 2006.PMID:16417420Review.
- Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD.Jackson C, Pearson B, Girdler S, Johnson J, Hamer RM, Killenberg S, Meltzer-Brody S.Jackson C, et al.Hum Psychopharmacol. 2015 Nov;30(6):425-34. doi: 10.1002/hup.2494. Epub 2015 Jul 19.Hum Psychopharmacol. 2015.PMID:26193781Clinical Trial.
- The multifactorial aetiology and management of premenstrual dysphoric disorder with leuprorelin acetate.Dunphy L, Boyle S, Wood F.Dunphy L, et al.BMJ Case Rep. 2023 Dec 30;16(12):e258343. doi: 10.1136/bcr-2023-258343.BMJ Case Rep. 2023.PMID:38160030
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical